Clinical Trial: Identification of Secreted Markers for Tumor Hypoxia in Patients With Head and Neck or Lung Cancers
Study Status: Recruiting
Recruit Status: Recruiting
Study Type: Observational
Official Title: Identification of Secreted Markers for Tumor Hypoxia in Patients With Head and Neck or Lung Cancers
Brief Summary: The purpose of this study is to identify and confirm new blood and tissue markers for prognosis and tumor hypoxia. Tumor hypoxia, or the condition of low oxygen in the tumor, has been shown to increase the risk of tumor spread and enhance tumor resistance to the standard treatment of radiation and chemotherapy in head and neck and lung cancers. We have recently identified several proteins or markers in the blood and in tumors (including osteopontin, lysyl oxidase, macrophage inhibiting factor and proteomic technology) in the laboratory that may be able to identify tumors with low oxygen levels or more aggressive behaving tumors.
Detailed Summary:
The endpoints of the study are
- To validate the prognostic significance of OPN in H&N and lung cancer patients and to monitor its level during active therapy and follow up for cancer surveillance.
- To identify a gene and protein signature for hypoxia in H&N and lung cancer patients.
Sponsor: Stanford University
Current Primary Outcome: Identification of Secreted Markers for Tumor Hypoxia through tissue collection [ Time Frame: before therapy, weekly during therapy ]
Original Primary Outcome:
Current Secondary Outcome:
Original Secondary Outcome:
Information By: Stanford University
Dates:
Date Received: December 4, 2007
Date Started: September 1998
Date Completion: April 2022
Last Updated: July 11, 2016
Last Verified: July 2016
